We classified patients according to NOD1 expression and ETBF presence and found that more than 76.9% of NOD1+ETBF+ patients were resistant to TNC, whereas almost 83.3% of non-NOD1+ETBF+ patients were sensitive to TNC (Fig. 2M), suggesting that the presence of ETBF and NOD1 expression together in tumors is a biomarker for chemoresistance in breast cancer. Here, NOD1 is linked to breast carcinoma.